The landscape of cholesterol management is undergoing a major transformation, with a newly approved oral medication, a twice-yearly injection, and updated national guidelines offering patients more options than ever before. Together, these developments could help millions of Americans lower their “bad” cholesterol and reduce their risk of heart attack and stroke.
In a significant step, the Food and Drug Administration (FDA) approved Lipfendra (enlicitide) on July 16, making it the first oral PCSK9 inhibitor for adults with high LDL cholesterol. The once-daily pill, which can be used alongside or instead of statins, produced striking results in clinical trials. In one study, patients saw their LDL cholesterol drop by about 56% after 24 weeks, while a second trial reported a 59% reduction. While these trials measured cholesterol levels, not heart events directly, the FDA recognizes LDL reduction as a validated surrogate marker for lower cardiovascular risk.
Just days later, a systematic review and meta-analysis published in JACC: Advances reinforced the promise of inclisiran, a synthetic drug given by injection only twice a year. Analyzing nine randomized controlled trials, researchers found that inclisiran led to a 49% greater reduction in LDL cholesterol compared with placebo, even among patients already taking statins. The FDA recently updated inclisiran’s label to permit its use alone or in combination with statin therapy, plus diet and exercise, for people with hypercholesterolemia. For patients who struggle with daily oral medications or who cannot tolerate statins, this long-acting option could improve adherence and outcomes.
These medication advances arrive alongside a major update to clinical guidance. Earlier this year, the American Heart Association, American College of Cardiology, and other medical organizations released new cholesterol guidelines that recommend earlier treatment, routine measurement of lipoprotein(a) to identify inherited risk, and use of a newer risk calculator called PREVENT. The guidelines also set lower LDL targets for high-risk patients and encourage individualized treatment decisions based on risk factors and imaging when appropriate.
The impact of these guidelines is already being quantified. A study in JAMA found that approximately 56.6% of U.S. adults aged 30 to 79, about 87.5 million people, are now eligible for statin therapy. That includes 21.5 million adults who would not have qualified under the previous 2018 recommendations. However, other research highlights persistent gaps: more than three-quarters of high-risk adults without cardiovascular disease and one-third of those with existing heart disease are not receiving recommended treatment. A separate analysis found that the PREVENT calculator reclassified about 21.5% of adults into different risk categories, with most moving to lower-risk groups.
Looking ahead, cardiologists remain cautiously optimistic. While the LDL-lowering effects of Lipfendra and inclisiran are well documented, outcomes trials are still needed to confirm that these reductions translate into fewer heart attacks and strokes. For now, the combination of new medications, updated guidelines, and a growing focus on individualized care offers renewed hope for the millions of Americans living with high cholesterol.